{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-089737","form_type":"8-K","ticker":"CGTX","cik":"0001455365","company_name":"COGNITION THERAPEUTICS INC","filed_at":"2025-09-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:44.023050+00:00","generated_at":"2026-05-17T06:36:59.283517+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"confidence":"low","headline":"Cognition Therapeutics' investor deck highlights Zervimesine Phase 3 progress","bullets":["Presentation focuses on Zervimesine, a once-daily oral therapeutic for neurodegenerative diseases.","Zervimesine is described as advancing toward Phase 3, but no specific trial dates or results disclosed.","No financial results, guidance, or material operational updates included in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-089737","json":"https://secwatch.observer/filing/0001104659-25-089737.json","markdown":"https://secwatch.observer/filing/0001104659-25-089737.md","text":"https://secwatch.observer/filing/0001104659-25-089737.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/0001104659-25-089737-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1455365/000110465925089737/tm2525997d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T06:36:59.283517+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}